2012-04-05 14:14
新合并公司将着重致力于血库、输血医学和细胞疗法
科罗拉多州莱克伍德--(美国商业资讯)--CaridianBCT和Terumo Transfusion已合并为Terumo BCT。Terumo BCT总部位于美国,成为侧重于血库、输血医学和细胞疗法的最大医疗器械公司之一。
Terumo BCT是泰尔茂株式会社(Terumo Corporation)的子公司,总部位于科罗拉多州莱克伍德。原CaridianBCT的总裁兼首席执行官David Perez将继续留任,担任Terumo BCT的总裁兼首席执行官。在2011年5月22日,Perez还被任命为泰尔茂株式会社血液管理部董事长。
基本情况:
- Terumo BCT是继2011年4月泰尔茂株式会社收购CaridianBCT之后,由CaridianBCT和Terumo Transfusion合并而组建的。
- Terumo BCT的总部位于科罗拉多州莱克伍德,是唯一一家全球总部位于日本之外的泰尔茂株式会社子公司。
- Terumo BCT拥有2,500个合作伙伴和客户,遍布全球120多个国家和地区,分别在布鲁塞尔、布宜诺斯艾利斯、香港和东京设有区域总部。
- Terumo BCT服务于3大主要客户群体:血液中心、医院及治疗性血液分离置换中心、生物技术及细胞处理机构。
重要讲话:
泰尔茂株式会社血液管理部董事长、Terumo BCT总裁兼首席执行官David Perez的讲话
"通过倾听来自于我们客户的宝贵观点和意见,并与他们紧密合作,我们才有机会进一步挖掘血液潜能,为全世界人民提供更加安全和更高品质的输血服务;帮助血液中心在更高生产率水平上进行运营;使更加广泛的疾病能够采用血液疗法进行治疗;帮助研究人员开发细胞疗法,从根本上改善医疗状况。最重要的一点是,Terumo BCT不仅具有帮助我们客户的潜能,而且还具有改善患者疗效的潜能。"
"对双方公司而言,这是一个激动人心的时刻。这是对业内两家领先企业进行的合并,双方公司都非常注重于其客户及其最终服务的患者群体,拥有相似的文化和价值体系。双方公司,即新组建的Terumo BCT,热衷于开发创新,并通过不断完善我们在各个方面提供的服务,致力于提高质量和客户满意度。"
主要信息资源:
关于Terumo BCT:
Terumo BCT在血液成分和细胞技术领域居全球领先地位,是唯一一家拥有血液分离置换采集、手动及自动全血处理和病原菌灭活独特组合的公司,此外,公司还在治疗性采集和细胞处理领域拥有领先技术。我们相信血液具有巨大潜能,能为患者提供比当今更多的治疗方法及更好的治疗效果。正是这一信念激励我们不断创新,并加强与客户间的紧密合作。
关于泰尔茂株式会社:
总部位于东京的泰尔茂株式会社(Terumo Corporation)是全球领先的医疗设备制造商之一,业务遍及160多个国家。该公司成立于1921年,致力于开发、制造和分销世界级医疗设备,包括应用于心胸外科、介入手术和输血医学的产品;该公司还生产广泛的应用于医院和医生办公室的注射器和皮下注射器针头产品。泰尔茂致力于为医疗保健市场提供重要的产品与服务以及响应医疗保健提供商和所服务人员的需求,从而为社会做贡献。泰尔茂株式会社的股票在东京证券交易所(No. 4543, Reuters代码<4543.T>,或Bloomberg 4543: JP)一部上市,并且是日本领先股票指数日经225(Nikkei 225)的成分股。
免责声明:本公告之原文版本乃官方授权版本。译文仅供方便了解之用,烦请参照原文,原文版本乃唯一具法律效力之版本。
联系方式:
Terumo BCT
Laura Fusco
全球企业通讯部
电话:+1.303.205.2546
press@caridianbct.com
April 2, 2012
CaridianBCT and Terumo Transfusion Become Terumo BCT
Company Focuses on Commitment to Blood Banking, Transfusion Medicine and Cellular Therapies
LAKEWOOD, Colo.—April 2, 2012—CaridianBCT and Terumo Transfusion have become Terumo BCT. Terumo BCT is one of the largest, U.S.-based medical device companies focused on blood banking, transfusion medicine and cellular therapies.
Terumo BCT, a subsidiary of Terumo Corporation, is headquartered in Lakewood, Colorado. President and CEO of CaridianBCT, David Perez, retains his position serving as Terumo BCT's President and CEO. Perez was also named Chairman of Terumo Corporation's Blood Management Division on May 22, 2011.
Key Facts:
- Terumo BCT was established through the integration of CaridianBCT and Terumo Transfusion, followingTerumo Corporation's acquisition of CaridianBCT in April 2011.
- Terumo BCT, headquartered in Lakewood, Colorado, is the only Terumo Corporation subsidiary with its global headquarters located outside of Japan.
- Terumo BCT has 2,500 associates and customers in more than 120 countries and territories, with regional headquarters in Brussels, Buenos Aires, Hong Kong and Tokyo.
- Terumo BCT serves three primary customer segments: Blood Centers, Hospital & Therapeutic Apheresis Centers and Biotech & Cell Processing.
Key Quotes:
David Perez, President and CEO, Terumo BCT, and Chairman, Terumo Corporation Blood Management Division
"By listening to our customers and collaborating closely with them, we have the opportunity to unlock the potential of blood to make even safer, higher-quality transfusions available to more people around the world; to help blood centers operate at an even higher level of productivity; to enable an ever-wider range of diseases to be treated with blood therapies; and to help researchers develop cellular therapies that could fundamentally improve health care. The bottom line is that Terumo BCT has the potential to not only help our customers but to improve patient outcomes."
"This is an exciting moment for both companies. We have united two industry leaders, both strongly focused on customers and the patients we ultimately serve, with similar cultures and value systems. Both organizations, now Terumo BCT, share a passion for developing and delivering innovation to our global customers, and a commitment to quality and delighting our customers through continuous improvement in all we do."
Key Resources:
About Terumo BCT:
Terumo BCT, a global leader in blood component and cellular technologies, is the only company with the unique combination of apheresis collections, manual and automated whole blood processing, and pathogen reduction coupled with leading technologies in therapeutic apheresis and cell processing. We believe in the potential of blood to do even more for patients than it does today. This belief inspires our innovation and strengthens our collaboration with customers.
About Terumo Corporation:
Tokyo-based Terumo Corporation is one of the world's leading medical device manufacturers with operations in more than 160 nations. Founded in 1921, the company develops, manufactures and distributes world-class medical devices including products for use in cardiothoracic surgery, interventional procedures and transfusion medicine; the company also manufactures a broad array of syringe and hypodermic needle products for hospital and physician office use. Terumo contributes to society by providing valued products and services to the health care market and by responding to the needs of health care providers and the people they serve. Terumo Corporation's shares are listed on the first section of the Tokyo Stock Exchange (No. 4543, Reuters symbol <4543.T>, or Bloomberg 4543: JP) and is a component of the Nikkei 225, Japan's leading stock index.
(Notice) Among the information that Terumo discloses, forecasts of financial performance on future projections contain potential risks and uncertainty since these are forecasts on projections made by Terumo based on limited information available at the moment of disclosure. Accordingly, it should be noted that actual results may differ from those forecasts on projections due to various factors. Factors affecting to actual results include, but are not limited to, changes in economic conditions surrounding Terumo, fluctuations of foreign exchange rates, and state of competition.
The market share information in this booklet is partly derived from our own independent research.